Christopher Rowland on Muck Rack

Christopher Rowland

Verified
Washington, D.C.
As seen in: The Washington Post, MSN, MSN Brasil, Yahoo Life, Terra, The Independent (UK), Yahoo Canada, Yahoo News, Yahoo News Australia, Yahoo News Malaysia, Yahoo News New Zealand and
Business of health reporter at The Washington Post. Previously: The Boston Globe.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting

|
By Ariana Eunjung Cha, Christopher Rowland 
| Toronto Sun
Skip to Content Now a growing body of research is raising another possibility: that these drugs may help protect against cancer. •   • You can save this article by registering for free here. Or sign-in if you have an account. (The Washington Post/The Washington Post illustration; iStock) jpg We independently select everything we recommend. Buying through us may earn us a commission, which supports our work. The story of GLP-1 drugs keeps getting bigger. Don't have an account?
Open in Who Shared Issue with article?

Seniors needed long-term care and rehab. Their private Medicare plans said no.

|
By Christopher Rowland 
| Yahoo Singapore
Christopher Rowland, (c) 2026 , The Washington Post Thu, 11 June 2026 at 9:28 pm UTC 5 min read Add Yahoo as a preferred source to see more of our stories on Google.
Open in Who Shared View Duplicates (4) Issue with article?

3 ways GLP-1 drugs could be getting better Original

|
By Christopher Rowland 
| Yahoo
Photo illustration of a group of weight loss medications on a white background. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) The enormous popularity of new weight-loss drugs often eclipses the downsides: the burden of weekly injections, rough gastrointestinal side effects, muscle and bone loss. That is shaping a race among drug manufacturers vying to roll out better options.
Open in Who Shared View Duplicates (5) Issue with article?
See all 846 licensed articles (1,002 Total)

Actions

Share this page

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified